Details for New Drug Application (NDA): 213867
✉ Email this page to a colleague
NDA 213867 describes TENOFOVIR ALAFENAMIDE FUMARATE, which is a drug marketed by Apotex and is included in one NDA. Additional details are available on the TENOFOVIR ALAFENAMIDE FUMARATE profile page.
The generic ingredient in TENOFOVIR ALAFENAMIDE FUMARATE is tenofovir alafenamide fumarate. There are forty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tenofovir alafenamide fumarate profile page.
The generic ingredient in TENOFOVIR ALAFENAMIDE FUMARATE is tenofovir alafenamide fumarate. There are forty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tenofovir alafenamide fumarate profile page.
Summary for 213867
| Tradename: | TENOFOVIR ALAFENAMIDE FUMARATE |
| Applicant: | Apotex |
| Ingredient: | tenofovir alafenamide fumarate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 25MG BASE | ||||
| Approval Date: | Mar 21, 2024 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
